Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Triumeq in Virologically Suppressed HIV-1 Adults
NCT02105987Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Apr 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02105987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105987.